AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 72 filers reported holding AMYLYX PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,433,297 | -23.2% | 952,119 | -9.5% | 0.00% | 0.0% |
| Q2 2023 | $22,688,319 | -14.3% | 1,051,846 | +16.5% | 0.00% | -33.3% |
| Q1 2023 | $26,480,729 | +47.9% | 902,547 | +86.3% | 0.00% | +50.0% |
| Q4 2022 | $17,901,129 | +136.3% | 484,469 | +80.1% | 0.00% | +100.0% |
| Q3 2022 | $7,575,000 | +813.8% | 269,070 | +524.2% | 0.00% | – |
| Q2 2022 | $829,000 | +52.4% | 43,106 | +1.8% | 0.00% | – |
| Q1 2022 | $544,000 | – | 42,345 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,756,050 | $35,415,000 | 3.44% |
| Boxer Capital, LLC | 2,200,000 | $28,270,000 | 1.45% |
| Alpha Wave Global, LP | 617,220 | $7,931,000 | 0.72% |
| Ikarian Capital, LLC | 396,654 | $5,097,000 | 0.67% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 768,603 | $9,877,000 | 0.58% |
| Ikarian Capital, LLC | 250,000 | $3,213,000 | 0.42% |
| 683 Capital Management, LLC | 677,714 | $7,685,000 | 0.41% |
| Perceptive Advisors | 1,474,107 | $18,942,000 | 0.38% |
| VIKING GLOBAL INVESTORS LP | 7,170,536 | $92,141,000 | 0.37% |
| Rock Springs Capital Management LP | 998,307 | $12,828,000 | 0.32% |